Apex Biotechnology (TPE:1733) Total Stockholders Equity : NT$1,717 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Total Stockholders Equity?

Apex Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$1,717 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Apex Biotechnology's Book Value per Share for the quarter that ended in Mar. 2024 was NT$17.18. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Apex Biotechnology's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.09.

Apex Biotechnology Total Stockholders Equity Historical Data

The historical data trend for Apex Biotechnology's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology Total Stockholders Equity Chart

Apex Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,675.79

1,645.39

1,752.73

1,817.32

1,796.43

Apex Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															1,712.75	1,740.71	1,780.22	1,796.43	1,716.81

Apex Biotechnology (TPE:1733) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Apex Biotechnology's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1716.807	-	0)	/	99.95
	=	17.18

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Apex Biotechnology's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(44.756	+	115.83)	/	1716.807
	=	0.09

Apex Biotechnology Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Apex Biotechnology (TPE:1733) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078

Website

https://www.apexbio.com

Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines